Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
Neoplasm Metastasis
DRUG: PF-07265807|DRUG: Sasanlimab|DRUG: Axitinib
Parts 1, 2, and 3: Number of participants with dose limiting toxicities (DLTs), DLTs will be evaluated during the first cycle (day 21) or two cycles (day 42). The number of DLTs will be used to determine the maximum tolerated dose (MTD), Baseline through day 21 or 42|Parts 1, 2 and 3: Number of participants with treatment emergent adverse events (AEs), AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy, Baseline through approximately 2 years|Parts 1, 2, and 3: Number of participants with laboratory abnormalities, Laboratory abnormalities as characterized by type, frequency, severity, and timing., Baseline through approximately 2 years|Part 4: Overall Response Rate (ORR), Response will be evaluable via radiographical tumor assessment by RECIST v1.1, Baseline through approximately 2 years|Part 4, Cohort 4: Complete Response (CR), Response will be evaluated via radiographical tumor assessment by RECIST v1.1, Baseline through approximately 2 years
Parts 1, 2, and 3: Maximum plasma concentration (Cmax) of PF-07265807 and its metabolite, Single dose (Cmax) and multiple dose (assuming steady state is achieved; Cmax,ss) pharmacokinetic (PK) parameters of PF-07265807 and its metabolite, Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 (if daily dosing) hours post dose; Cycle 1 Day 7, Cycle 2 Days 1 and 14 predose and 2 hours post dose; Cycle 3 Days 1 and 14 predose|Parts 2 and 3: Maximum plasma concentration (Cmax) of sasanlimab, Single dose (Cmax) pharmacokinetic (PK) parameters of sasanlimab, Through study completion, an average of 1 year|Part 3: Maximum plasma concentration at steady state (Cmax,ss) of axitinib, Multiple dose (assuming steady state is achieved; Cmax,ss) pharmacokinetic (PK) parameters of axitinib, Each cycle is 21 days. Cycle 1 Day 1 predose; Cycle 1 Day 14 predose, 0.5,1,2,4, and 8 hours post dose|Parts 1, 2, and 3: Time to reach maximum plasma concentration (Tmax) of PF-07265807 and its metabolite, Single dose (Tmax) and multiple dose (assuming steady state is achieved; Tmax,ss) pharmacokinetic parameters of PF-07265807 and its metabolite, Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 (if daily dosing) hours post dose; Cycle 1 Day 7, Cycle 2 Days 1 and 14 predose and 2 hours post dose; Cycle 3 Days 1 and 14 predose|Parts 2 and 3: Time to reach maximum plasma concentration (Tmax) of sasanlimab, Single dose (Tmax) pharmacokinetic parameters of sasanlimab, Through study completion, an average of 1 year|Part 3: Time to reach maximum plasma concentration at steady state (Tmax,ss) of axitinib, Multiple dose (assuming steady state is achieved; Tmax,ss) pharmacokinetic parameters of axitinib, Each cycle is 21 days. Cycle 1 Day 1 predose; Cycle 1 Day 14 predose, 0.5,1,2,4, and 8 hours post dose|Parts 1, 2, and 3: Area under the curve from the time of dose to the last measurable concentration (AUClast) of PF-07265807 and its metabolite, Single dose (AUClast) pharmacokinetic parameters of PF-07265807 and its metabolite, Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 (if daily dosing) hours post dose; Cycle 1 Day 7, Cycle 2 Days 1 and 14 predose and 2 hours post dose; Cycle 3 Days 1 and 14 predose|Parts 2 and 3: Area under the curve from the time of dose to the last measurable concentration (AUClast) of sasanlimab, Single dose (AUClast) pharmacokinetic parameters of sasanlimab, Through study completion, an average of 1 year|Parts 1, 2, and 3: Area under the curve from the time of dose to the time of the subsequent dose (AUCtau) at steady state of PF-07265807 and its metabolite, Multiple dose assuming steady state is achieved (AUCtau,ss) pharmacokinetic parameters of PF-07265807 and its metabolite, Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 (if daily dosing) hours post dose; Cycle 1 Day 7, Cycle 2 Days 1 and 14 predose and 2 hours post dose; Cycle 3 Days 1 and 14 predose|Part 3: Area under the curve from the time of dose to the time of the subsequent dose (AUCtau) at steady state of axitinib, Multiple dose assuming steady state is achieved (AUCtau,ss) pharmacokinetic parameters of axitinib, Each cycle is 21 days. Cycle 1 Day 1 predose; Cycle 1 Day 14 predose, 0.5,1,2,4, and 8 hours post dose|Parts 1, 2, and 3: Terminal elimination half-life (t1/2) of PF-07265807 and its metabolite, As data permits, single dose (t1/2) pharmacokinetic parameters of PF-07265807 and its metabolite, Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 (if daily dosing) hours post dose; Cycle 1 Day 7, Cycle 2 Days 1 and 14 predose and 2 hours post dose; Cycle 3 Days 1 and 14 predose|Parts 2 and 3: Terminal elimination half-life (t1/2) of sasanlimab, As data permits, single dose (t1/2) pharmacokinetic parameters of sasanlimab, Through study completion, an average of 1 year|Parts 1, 2, and 3: Area under the curve from the time of dose extrapolated to infinity (AUCinf) of PF-07265807 and its metabolite, As data permits, single dose (AUCinf) pharmacokinetic parameters of PF-07265807 and its metabolite, Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 (if daily dosing) hours post dose; Cycle 1 Day 7, Cycle 2 Days 1 and 14 predose and 2 hours post dose; Cycle 3 Days 1 and 14 predose|Parts 2 and 3: Area under the curve from the time of dose extrapolated to infinity (AUCinf) of sasanlimab, As data permits, single dose (AUCinf) pharmacokinetic parameters of sasanlimab, Through study completion, an average of 1 year|Parts 1, 2, and 3: Apparent oral clearance (CL/F) of PF-07265807, As data permits, single dose (CL/F) and multiple dose pharmacokinetic parameters of PF-07265807, Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 (if daily dosing) hours post dose; Cycle 1 Day 7, Cycle 2 Days 1 and 14 predose and 2 hours post dose; Cycle 3 Days 1 and 14 predose|Parts 2 and 3: Apparent clearance (CL/F) of sasanlimab, As data permits, single dose (CL/F) pharmacokinetic parameters of sasanlimab, Through study completion, an average of 1 year|Parts 1, 2, and 3: Apparent terminal volume of distribution (Vz/F) of PF-07265807, As data permits, single dose (Vz/F) and multiple dose (Vss/F) pharmacokinetic parameters of PF-07265807, Each cycle is 21 days. Cycle 1 Days 1 and 14, predose, 0.5,1,2,4,8 and 24 (if daily dosing) hours post dose; Cycle 1 Day 7, Cycle 2 Days 1 and 14 predose and 2 hours post dose; Cycle 3 Days 1 and 14 predose|Parts 2 and 3: Apparent terminal volume of distribution (Vz/F) of sasanlimab, As data permits, single dose (Vz/F) pharmacokinetic parameters of sasanlimab, Through study completion, an average of 1 year|Parts 1, 2, and 3: ORR, Response will be evaluable via radiographical tumor assessment by RECIST v1.1, Baseline through approximately 2 years|Part 4: Number of participants with treatment emergent AEs, AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy, Baseline through approximately 2 years|Part 4: Number of participants with laboratory abnormalities, Laboratory abnormalities as characterized by type, frequency, severity, and timing, Baseline through approximately 2 years|Part 4: Trough concentration (Ctrough) of PF-07265807 and its metabolite, Predose (Ctrough) pharmacokinetic (PK) parameter of PF-07265807 and its metabolite, Each cycle is 21 days. Cycle 1 Days 1 and 14 predose, 2, 4 hours post dose; Cycle 1 Day 7 predose and 2 hours post dose; Cycle 2 Days 1 and 14 predose|Part 4: Post dose concentration (Cmax) of PF-07265807 and its metabolite, Post dose (Cmax) pharmacokinetic (PK) parameter of PF-07265807 and its metabolite, Each cycle is 21 days. Cycle 1 Days 1 and 14 predose, 2, 4 hours post dose; Cycle 1 Day 7 predose and 2 hours post dose; Cycle 2 Days 1 and 14 predose|Part 4, Cohorts 2, 3 and 4: Trough concentration (Ctrough) of sasanlimab, Predose (Ctrough) pharmacokinetic (PK) parameter of sasanlimab, Each cycle is 21 days. Cycle 1 Days 1, 7, and 14, Cycle 2 Day 1, Cycle 7 Day 1, and every 6 cycles thereafter predose|Part 4, Cohort 4: Trough concentration (Ctrough) of axitinib, Predose (Ctrough) pharmacokinetic (PK) parameter of axitinib, Each cycle is 21 days. Cycle 1 Day 1 predose; Cycle 1 Day 14 predose, 2, and 4 hours post dose|Parts 2, 3, and 4 Cohorts 2-4: Immunogenicity of sasanlimab when given in combination, Incidence and titer of anti-sasanlimab ADA response, Through study completion, an average of 1 year|Duration of Response, Response will be evaluable via radiographical tumor assessment by RECIST v1.1, Baseline through approximately 2 years|Disease Control Rate, Response will be evaluable via radiographical tumor assessment by RECIST v1.1, Baseline through approximately 2 years|Progression Free Survival, Response will be evaluable via radiographical tumor assessment by RECIST v1.1, Baseline through approximately 2 years
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors